Ontology highlight
ABSTRACT:
SUBMITTER: Wagle N
PROVIDER: S-EPMC3947296 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature
Wagle Nikhil N Van Allen Eliezer M EM Treacy Daniel J DJ Frederick Dennie T DT Cooper Zachary A ZA Taylor-Weiner Amaro A Rosenberg Mara M Goetz Eva M EM Sullivan Ryan J RJ Farlow Deborah N DN Friedrich Dennis C DC Anderka Kristin K Perrin Danielle D Johannessen Cory M CM McKenna Aaron A Cibulskis Kristian K Kryukov Gregory G Hodis Eran E Lawrence Donald P DP Fisher Sheila S Getz Gad G Gabriel Stacey B SB Carter Scott L SL Flaherty Keith T KT Wargo Jennifer A JA Garraway Levi A LA
Cancer discovery 20131121 1
Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP-ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. We performed whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq) on pretreatment and drug-resistant tumors from five patients with acquired res ...[more]